| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00888615 | Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma | Drug: Elesclomol Sodium|Drug: Paclitaxel | Gynecologic Oncology Group|National Cancer Institute (NCI) | Phase 2 | 2010-12-01 | 2014-12-23 |
| NCT00827203 | Metastatic Solid Tumors | Drug: Elesclomol Sodium | Synta Pharmaceuticals Corp. | Phase 1 | 2009-01-01 | 2009-03-06 |
| NCT01280786 | Acute Myeloid Leukemia | Drug: Elesclomol Sodium | Synta Pharmaceuticals Corp. | Phase 1 | 2011-01-01 | 2014-01-31 |
| NCT00808418 | Prostate Cancer | Drug: Elesclomol Sodium|Drug: Docetaxel | Synta Pharmaceuticals Corp. | Phase 1 | 2008-11-01 | 2014-01-31 |
| NCT00522834 | Melanoma | Drug: Elesclomol (STA-4783)|Drug: Paclitaxel | Synta Pharmaceuticals Corp. | Phase 3 | 2007-08-01 | 2014-01-31 |
| NCT00088114 | Neoplasms | Drug: STA-4783/paclitaxel | Synta Pharmaceuticals Corp. | Phase 1 | 2003-01-01 | 2014-03-05 |
| NCT00084214 | Melanoma | Drug: STA-4783|Drug: Paclitaxel | Synta Pharmaceuticals Corp. | Phase 1|Phase 2 | 2004-05-01 | 2014-03-05 |
| NCT00088088 | Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer | Drug: Paclitaxel|Drug: Carboplatin|Drug: STA 4783 | Synta Pharmaceuticals Corp. | Phase 1|Phase 2 | 2004-03-01 | 2008-12-03 |
| NCT00087997 | Soft Tissue Sarcoma | Drug: STA-4783 | Synta Pharmaceuticals Corp. | Phase 2 | 2004-07-01 | 2006-06-19 |
